Photopheresis

A 1987 New England Journal of Medicine publication introduced photopheresis involving 8-methoxypsoralen., now standard U.S. Food and Drug Administration (FDA) therapy for cutaneous T-cell lymphoma. Evidence suggests that this treatment might help treat graft-versus-host disease, though this evidence is largely observational; controlled trials are needed to support this use. Photopheresis has also been successful in treating epidermolysis bullosa acquisita when all other treatments have been ineffective.

Minimal observed side effects for patients receiving photopheresis include hypotension and syncope resulting from volume shifts during leukapheresis phase of treatment. Photopheresis is also an experimental treatment for patients with cardiac, pulmonary and renal allograft rejection, graft-versus-host disease, autoimmune diseases, nephrogenic systemic fibrosis and ulcerative colitis.